FINWIRES · TerminalLIVE
FINWIRES

SHE:301263

3 stories mentioning SHE:301263Updated just now

Every FINWIRES story that references SHE:301263, newest first.

What's the latest news on SHE:301263?

Asia

Guangdong Taienkang Pharmaceutical Unit Gets Drug Regulator's Approval for Hypertension Tablets

Guangdong Taienkang Pharmaceutical's (SHE:301263) wholly owned subsidiary Shandong Huabo Kaisheng Biotechnology received China's National Medical Products Administration's approval for Labetalol Hydrochloride tablets, according to a Shenzhen bourse filing on Tuesday.The drug, available in 0.1-gram and 0.2-gram specifications, is primarily used to treat hypertension, including hypertensive disorders during pregnancy, the filing said.Shares of Guangdong Taienkang Pharmaceutical added more than 1% in recent trade.

SHE:301263
Asia

Guangdong Taienkang Pharmaceutical Directors Approve Capital Increase

Guangdong Taienkang Pharmaceutical (SHE:301263) directors approved the change in the company's registered capital and total share capital.The registered capital rose to 510.6 million yuan from 425.5 million yuan, while the number of shares increased to 510.6 million from 425.5 million, according to a Thursday filing with the Shenzhen bourse.

SHE:301263
Asia

Guangdong Taienkang Pharmaceutical Reports Positive CKBA Cream Trial Results

Guangdong Taienkang Pharmaceutical (SHE:301263) said its Phase IIa clinical trial for CKBA Cream in treating papulopustular rosacea has completed enrollment of all 15 subjects, with positive preliminary data prompting early initiation of Phase IIb.The trial showed significant inflammatory lesion reduction after eight weeks and no serious adverse reactions, according to a Monday filing with the Shenzhen bourse.Shares of the drugmaker rose 1% in recent trade.

SHE:301263

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:301263 in your portfolio
WheelAI
WheelAI
Analyze SHE:301263 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:301263